Mark Brosius, who serves as senior vice president and chief of manufacturing and supply chain at Intuitive Surgical Inc (NASDAQ:ISRG), sold 1,293 shares of the company's stock in two separate block trades on March 6 and March 9, 2026, according to an SEC filing made public after the transactions.
The first tranche, executed on March 6, consisted of 648 shares sold at $490.19 per share. The second tranche, completed on March 9, involved 645 shares at $485.01 per share. Together the two sales produced gross proceeds of $630,474.
Following these disposals, Brosius is reported to directly own 1,613 shares of Intuitive Surgical. The filing notes that the sales were conducted under a pre-existing trading arrangement compliant with SEC Rule 10b5-1. That plan is scheduled to remain in effect until February 14, 2027.
At the time of reporting, the company's stock price was $486.61. The share price is down nearly 13% year-to-date, while the market capitalization stands at $172.53 billion.
Valuation and research notes in the filing's accompanying market context cite a price-to-earnings ratio of 61.94 and an InvestingPro assessment that the shares trade above the service's calculated Fair Value. No further valuation methodology is included in the filing.
Operationally and on the results front, Intuitive Surgical reported fourth-quarter 2025 revenues of $2.87 billion, a 19% increase from the prior year. That top-line figure exceeded both Stifel and consensus expectations of $2.72 billion. The company also posted earnings per share that came in ahead of estimates, a point highlighted by Truist Securities when noting revenue strength.
In strategic moves, Intuitive Surgical completed the acquisition of distribution businesses across Southern Europe, a transaction that brings direct company operations to Italy, Spain, Portugal, Malta, San Marino, and other associated territories. The company said the change will enable direct operations in those markets.
Following the quarter and the strategic expansion, several analysts maintained or raised their recommendations on the stock. Stifel reiterated a Buy rating with a $670.00 price target. Truist Securities also kept a Buy rating and set a $650.00 target, citing improved gross margin guidance for 2026. TD Cowen initiated coverage with a Buy and a $660.00 target, pointing to growth potential within the MedTech segment. Freedom Capital Markets upgraded the shares from Hold to Buy and raised its price target to $610.00, citing optimism tied to the rollout of the da Vinci 5 surgical system and its potential to bolster sales and procedure volumes through 2026.
This filing provides a clear record of the insider transactions, the remaining beneficial ownership for the named executive, and the existence and duration of the 10b5-1 trading plan. At the same time, the company continues to report revenue growth, confirm operational expansions in Southern Europe, and attract reaffirmed or new Buy ratings from a range of brokerage analysts.